This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Urpo K. Rinne, MD; Reijo Marttila, MD; Vesa Sonninen, MD

Arch Neurol. 1977;34(10):626-629.

Abstract
• The relationship between dopamine receptor activation and the relief of parkinsonian clinical features was studied in 40 patients with Parkinson's disease. Treatment with dopamine receptor agonists, piribedil or bromocriptine, decreased significantly both the basal level and probenecid-induced accumulations of homovanillic acid (HVA) in the CSF. But there were no changes in the concentrations of 5-hydroxyindole acetic acid (5-HIAA). Correlation analyses showed that patients who improved with both the dopamine agonists used had significantly lower probenecid response of HVA in the CSF and a less severe disease condition than those without beneficial effect. This relationship between dopamine receptor activation and improvement of parkinsonian disability suggests that the therapeutic efficacy of dopamine receptor agonists depends on the functional capacity of brain dopaminergic mechanisms.

Author Affiliations
From the Department of Neurology, University of Turku, Turku, Finland.

Footnotes
Accepted for publication Feb 28, 1977.

Reprint requests to the Department of Neurology, University of Turku, SF-20520 Turku 52, Finland (Dr Rinne).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?